From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks

• Published in: Thrombosis and haemostasis Vol. 119; no. 11; p. 1720
• Main Authors: Martins Lima, Augusto, Martins Cavaco, Ana C, Fraga-Silva, Rodrigo A, Eble, Johannes A, Stergiopulos, Nikolaos
• Format: Journal Article
• Language: English
• Published: Germany 01.11.2019
• Subjects: Animals; Blood Platelets - drug effects; Blood Platelets - metabolism; Fibrinolytic Agents - adverse effects; Fibrinolytic Agents - therapeutic use; Hemorrhage - chemically induced; Hemostasis - drug effects; Humans; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - therapeutic use; Platelet Membrane Glycoproteins - antagonists & inhibitors; Platelet Membrane Glycoproteins - metabolism; Risk Assessment; Signal Transduction; Thrombosis - blood; Thrombosis - drug therapy; Treatment Outcome

Despite significant advances in the treatment of thrombogenic diseases, antiplatelet therapies are still associated with a high bleeding risk. Consequently, potential benefits of preventing thromboembolic events by pharmacological agents need to be balanced with the potential harm of inducing hemorr...